XGN is expected to report earnings to rise 109.19% to -33 cents per share on November 12
Q3'24
Est.
$-0.33
Q2'24
Beat
by $0.18
Q1'24
Beat
by $0.17
Q4'23
Beat
by $0.12
Q3'23
Beat
by $0.16
The last earnings report on August 05 showed earnings per share of -15 cents, beating the estimate of -34 cents. With 62.01K shares outstanding, the current market capitalization sits at 27.06M.
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases